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ABSTRACT
Cirrhosis is the final stage of chronic liver disease and has many causes, including viral hepatitis, excessive 
alcohol intake, and non-alcoholic steatohepatitis. When decompensated cirrhosis develops, complications 
occur that affect quality of life and patient survival. Cirrhosis has a large burden of disease and is 
responsible for almost 2% of deaths in Europe. Cirrhotic patients are in need of early diagnosis and a 
careful follow-up for the prevention and detection of complications. The ultimate treatment for end-stage 
cirrhosis is liver transplantation. This review will cover clinical aspects of cirrhosis and uncover future trends 
in the care of these patients. 
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INTRODUCTION
Cirrhosis is the final stage of chronic liver disease. 
It results in distortion of the hepatic architecture 
by fibrosis, and the formation of regenerative 
nodules.1 It is the result of progressive liver fibrosis 
caused by chronic liver diseases, including viral 
hepatitis, alcoholic liver disease, non-alcoholic 
steatohepatitis (NASH), autoimmune liver disease, 
and genetic disorders, amongst others. Recent 
reports support the finding that the early stages of 
cirrhosis are reversible on a microscopic level with 
adequate treatment of the underlying liver disease.2 
However, at more advanced stages, cirrhosis is 
considered irreversible. Cirrhosis is the source of a 
variety of complications, which result in a reduction 
in the life expectancy of these patients.3 At this 
stage, liver transplantation is the only curative 
treatment option.4 
EPIDEMIOLOGY AND AETIOLOGY 
Cirrhosis has a large burden of disease. It is the 
eighth leading cause of death and is responsible 
for 1.2% of all deaths in the USA.5 According to 
the Global Burden of Disease study, the worldwide 
prevalence of cirrhosis is increasing.6 In the USA, 
the most common causes of cirrhosis are chronic 
hepatitis C virus (HCV), alcoholic liver disease, and 
non-alcoholic liver disease.7 In Europe, liver cirrhosis 
accounts for 1.8% of all deaths, amounting to 
170,000 deaths per year.3 Worryingly, the reported 
incidence of cirrhosis remains stable or is increasing 
in several countries, including both the UK8 and 
Ireland.3 In Europe, the main causes are alcoholic 
liver disease, NASH, and HCV.3 The four most 
frequent causes of cirrhosis worldwide are chronic 
hepatitis B virus (HBV) and HCV, alcoholic liver 
disease, non-alcoholic fatty liver disease (NAFLD), 
and haemochromatosis. A variety of other 
diseases can result in cirrhosis, although these are 
less frequent.9 
Alcohol 
Excessive alcohol intake remains the number one 
cause of cirrhosis in Western countries. A daily 
intake of ≥60 g/day for men, and ≥40 g/day for 
women is considered harmful. Chronic intake of 
alcohol can also accelerate the natural progression 
of chronic HBV or HCV,10 and haemochromatosis. 
Alcohol abstinence is the cornerstone of treatment 
and can reverse the disease course.11
Viral Hepatitis 
Chronic HBV and HCV are leading causes of 
cirrhosis, especially in endemic regions like South 
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East Asia and Sub-Saharan Africa. According to 
the disease stage, finite treatment with pegylated 
interferon or long-term therapy with nucleos(t)ide 
analogues is appropriate in HBV patients.12 The 
introduction of interferon-free treatment for HCV 
has been important, as it has resulted in improved 
treatment response without significant side 
effects.13 However, access to these new direct-acting 
agents remains a challenge due to high costs. 
Hepatitis A and E do not develop into chronic 
hepatitis in immunocompentent patients and are 
not considered risk factors for cirrhosis. 
Non-Alcoholic Fatty Liver Disease  
NAFLD is related to the presence of metabolic 
syndrome in association with obesity, diabetes, 
and/or arterial hypertension. A subset of these 
patients will develop signs of NASH, which can lead 
to the development of fibrosis and subsequently 
cirrhosis.14,15 It is an increasing health problem, 
especially in the Western world.6 Treatment is based 
on dietary measures and exercise.14
Haemochromatosis 
Hereditary haemochromatosis is an autosomal 
recessive disorder characterised by excessive 
intestinal absorption of dietary iron, which results 
in a pathological increase in total body iron stores.16 
End-organ liver damage can occur, in turn leading 
to cirrhosis. Phlebotomy has been indicated to 
remove excessive iron stores.17
Autoimmune Hepatitis 
Autoimmune hepatitis is a rare disease affecting 
16–18 cases per 100,000 inhabitants in Europe. 
More than 30% of adult patients and ~50% 
of children have cirrhosis at diagnosis, due 
to an insidious disease course.18 Treatment is 
based on immunosuppressive agents including 
corticosteroids and azathioprine.18 
Primary Biliary Cholangitis and Primary 
Sclerosing Cholangitis 
Primary biliary cholangitis (PBC) and primary 
sclerosing cholangitis (PSC) are autoimmune 
diseases that affect the small and the large bile 
ducts, respectively. PBC can lead to progressive 
fibrosis resulting in cirrhosis. In PSC patients, 
prolonged extrahepatic cholestasis can induce the 
development of portal fibrosis leading to cirrhosis.19 
Ursodeoxycholic acid can slow down disease 
progression in PBC and can be used in PSC.20 
In PBC, newer agents, like obeticholic acid, are 
promising treatment options.21
Rare Causes of Cirrhosis 
Other causes of cirrhosis include a reaction to drugs, 
Budd-Chiari syndrome, Wilson’s disease, alpha-1 
antitrypsin deficiency, granulomatous liver diseases, 
right-sided heart failure, and veno-occlusive disease 
amongst others.9 A specific aetiology can be 
determined in 85–90% of patients.22
CLINICAL MANIFESTATION 
Cirrhosis can be compensated without overt 
complications, or decompensated with the 
appearance of complications. The three major 
complications of cirrhosis are the consequences of 
portal hypertension (e.g. ascites, variceal bleeding, 
etc.), hepatocellular insufficiency (e.g. icterus), or 
the appearance of hepatocellular carcinoma (HCC). 
Patients with compensated cirrhosis may present 
with nonspecific symptoms or may even be 
asymptomatic. They can complain of anorexia, 
weight loss, or fatigue. When decompensation 
develops, patients may present with jaundice, 
pruritus, signs of upper gastrointestinal bleeding, 
abdominal distension due to ascites, or confusions 
due to hepatic encephalopathy.23 Hypogonadism 
may occur in men, which can manifest as 
impotence, infertility, or loss of libido.24 In women, 
amenorrhoea or irregular menstrual bleeding are 
common.25 Typical signs at clinical examination 
include jaundice, stellate angiomas, palmar 
erythema, foetor hepaticus, asterixis, signs of 
hypogonadism, and feminisation in males. Other 
signs include indicators of portal hypertension such 
as ascites, cutaneous collateral venous circulation, 
and splenomegaly.23 
DIAGNOSIS 
Laboratory Findings 
Laboratory abnormalities may be the first 
indication of liver cirrhosis. Though bilirubin levels 
may be normal in compensated cirrhosis, 
the levels rise as cirrhosis progresses. Levels of 
aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) are moderately elevated in 
cirrhosis; however, normal aminotransferase levels 
do not exclude cirrhosis. Alkaline phosphatase is 
usually mildly elevated in cirrhosis. Levels higher 
than 2 or 3-times the upper limit of normal suggest 
an underlying cholestatic liver disease, such as 
EUROPEAN MEDICAL JOURNAL  •  August 2016   EMJ  EUROPEAN MEDICAL JOURNAL EUROPEAN MEDICAL JOURNAL  •  August 2016   EMJ  EUROPEAN MEDICAL JOURNAL 112 113
PSC or PBC.20 Gamma-glutamyl transpeptidase 
levels correlate well with alkaline phosphatase, 
but are more elevated in alcohol induced chronic 
liver disease.26 
Once the synthetic function of the liver is 
affected, albumin levels decrease and prothrombin 
time levels increase as key proteins involved 
in the coagulation cascade are produced in 
hepatocytes. Low platelets can appear in the case 
of hypersplenism.27  
Imaging  
Ultrasonography is the first step in liver imaging. 
It is non-invasive, widely available, affordable, and 
well accepted by patients. Liver volume can be 
normal, enlarged, or diminished, especially in 
advanced cirrhosis.28 Often a nodular deformation 
of the liver can be observed. Other typical signs 
include atrophy of the right lobe of the liver, 
and hypertrophy of the caudate or left lobes. 
When portal hypertension develops, Doppler 
imaging can reveal an enlarged portal vein, enlarged 
collateral veins, and decreased portal flow.29 
Ultrasonography is useful for the detection of 
hepatic nodules and is the backbone of screening 
programmes for the early detection of HCC.30,31 
Detection of hepatic nodules demands further 
characterisation using computed tomography or 
magnetic resonance imaging.
Non-Invasive Markers of Cirrhosis 
Hepatologists are increasingly adopting the 
use of non-invasive markers of fibrosis and 
cirrhosis. These include biological markers and 
transient elastography (TE). Liver fibrosis can be 
staged using 1-dimensional ultrasound (FibroScan®, 
Echosens, France),32 which measures the velocity 
of a low-frequency (50 Hz) elastic shear wave 
propagating through the liver. The stiffer the tissue, 
the faster the shear wave propagates. Ultrasound 
elastography can currently be performed based 
on two physical principles: strain displacement/ 
imaging, and shear wave imaging and 
quantification.33 The latter includes point shear 
wave elastography (pSWE), also known as acoustic 
radiation force impulse imaging (ARFI; Virtual 
touch tissue quantification™, Siemens Healthcare; 
elastography point quantification, ElastPQ™, 
Philips) and 2D-shear wave elastography (2D-SWE; 
Aixplorer™ Supersonic Imagine, France). A major 
advantage of pSWE/ARFI is that it can be easily 
implemented on modified commercial ultrasound 
machines (Acuson 2000/3000 Virtual Touch™ 
tissue quantification, Siemens Healthcare, Germany; 
ElastPQ, iU22xMATRIX, Philips, Netherlands). This 
results in a combined approach of conventional 
ultrasonography with TE.34 Correct interpretation 
of pSWE/ARFI results should systematically take 
into account potentially confounding parameters: 
fasting for at least 2 hours, levels of transaminases 
(<5-times the upper limit of normal), absence of 
extrahepatic cholestasis, and absence of right heart 
failure.33 According to the European Association 
for the Study of the Liver (EASL) clinical practice 
guidelines, TE is a reliable method for the diagnosis 
of cirrhosis in patients with chronic liver diseases. 
TE is generally better at ruling-out rather than 
suggesting cirrhosis and has a negative predictive 
value >90%.34
FibroTest©, a patented biomarker (combining 
six serum markers with the age and gender 
of the patient: alpha-2-macroglobulin, haptoglobin, 
apolipoprotein A1, gamma-glutamyl transpeptidase, 
total bilirubin, and ALT), and APRI (AST to Platelet 
Ratio Index calculator) are the most widely used 
and validated biological markers.35 Fibrotest and 
APRI show an area under a receiver operating 
characteristic curve (AUROC) of 0.86 and 0.84,36 
respectively, for the diagnosis of cirrhosis. 
Liver Biopsy 
The gold standard for the diagnosis of cirrhosis is 
a histological examination. However, this should 
not be performed in all cirrhotic patients. A biopsy 
should be considered in patients in whom the 
diagnosis is in question, and when knowledge of a 
specific diagnosis is likely to alter the management 
of the disease.37 A liver biopsy can be performed 
percutaneously, transjugularly, or laparoscopically. 
There is an inherent risk of bleeding, and severe 
bleeding occurs in between 1 in 2,500 and 1 in 
10,000 biopsies performed using an intercostal 
percutaneous approach.37  
MAJOR COMPLICATIONS  
Cirrhotic patients are at risk for the development 
of complications, therefore cirrhotic patients should 
be observed more closely for decompensated 
cirrhosis. Once decompensation develops, 
the patient should be considered for liver 
transplantation.4 Many complications of cirrhosis 
develop as a result of portal hypertension, an 
increased pressure in the portal circulation defined 
as an elevation of the hepatic venous pressure 
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gradient to >5 mmHg.38 The haemodynamic 
abnormalities associated with portal hypertension 
cause the most severe complications of 
cirrhosis, including ascites, hepatic encephalopathy, 
and bleeding from gastro-oesophageal varices. 
Ascites is the accumulation of fluid in the 
peritoneal cavity. It is treated with diuretics 
and sodium restriction. Some patients require 
repeated therapeutic paracentesis, or transjugular 
intrahepatic portosystemic shunt (TIPS) 
placement.39 In patients with ascites, spontaneous 
bacterial peritonitis (SBP) may occur. Patients 
may be asymptomatic, present with altered 
mental status, or be seriously ill with a high fever, 
abdominal tenderness, and pain. The diagnosis 
is established by an elevated ascitic fluid 
absolute polymorphonuclear leukocyte count 
(≥250 cells/mm³). The mortality is high if prompt 
antibiotic treatment and albumin substitution are 
not initiated.39
Hepatorenal syndrome (HRS) can develop in 
patients with advanced cirrhosis. HRS is the 
development of renal failure in patients with 
advanced chronic liver disease who have portal 
hypertension and ascites.40 Around 40% of these 
patients will develop HRS during the natural history 
of their disease. It is caused by vasoconstriction of 
the renal circulation and intense systemic arteriolar 
vasodilatation, which results in reduced systemic 
vascular resistance and arterial hypotension. 
Following liver transplantation, the histological 
appearance of the kidneys is normal and the 
kidneys often resume normal function.39 Treatment 
of HRS is based on the treatment of the 
precipitating factors; adequate volume replacement 
with albumin and vasoconstriction therapy with 
vasopressin analogues, such as terlipressin.39
Variceal haemorrhage is a dramatic event that 
typically presents as haematemesis and/or 
melaena. The mortality rate is high (20%, 30-day 
mortality) and treatment requires a multidisciplinary 
approach41 including antibiotic treatment and 
endoscopic haemostasis. In selected patients, 
early TIPS placement can increase survival.42 
A typical complication of cirrhosis is the occurrence 
of portal vein thrombosis (PVT). According to a 
large prospective trial in France, the 5-year 
cumulative incidence of PVT was 10.7%.41 PVT is 
associated with the severity of liver disease at 
baseline and anticoagulation is indicated in patients 
waiting for liver transplantation.43
Hepatic encephalopathy encompasses a spectrum 
of potentially reversible neuropsychiatric 
abnormalities including confusion, altered level 
of consciousness, and coma.44 Signs can easily be 
overlooked when they are limited to psychomotor 
slowing, a lack of attention, or sleep disturbances. 
Hepatic encephalopathy can be scored using 
the West Haven criteria. A typical sign of 
encephalopathy is the presence of asterixis. 
Treatment is based upon addressing the 
precipitating factors using synthetic disaccharides 
(e.g. lactulose) and nonabsorbable antibiotics 
(e.g. rifaximin).44
Liver cirrhosis is the most important risk factor for 
the development of HCC. HCC represents up to 
85% of the primary liver cancer burden.45 In patients 
with compensated cirrhosis the annual incidence 
of HCC ranges from 1–8%.46 It is mandatory for an 
ultrasonography to be taken every 6 months to 
ensure early detection of HCC.47,48
FOLLOW-UP, PREVENTION OF 
COMPLICATIONS, AND TREATMENT 
The natural course of cirrhosis is variable and can 
be well tolerated for many years. In these patients 
the primary goal should be to prevent the 
occurrence of complications. Slowing or even 
reversing the progression of liver disease can 
be achieved by addressing the underlying liver 
disease. Abstinence from alcohol improves survival 
in alcoholic cirrhosis.49 Achieving a sustained viral 
response in HCV with antiviral treatment lowers 
liver-related mortality.50  
The presence of impaired hepatic metabolism 
and renal excretion denotes a need for caution 
with many medications, which may subsequently 
necessitate dose adjustments or should even be 
avoided.49,51 Nephrotoxic agents can precipitate HRS 
and should be used cautiously. Careful monitoring 
for the development of complications and, 
if possible, the prevention of complications, is the 
cornerstone of the treatment of a cirrhotic patient. 
Cirrhotic patients should undergo screening 
for oesophageal varices with upper endoscopy. 
However, according to the recent Baveno VI 
guidelines, patients with a liver stiffness <20 kPa, 
and a platelet count >150,000 can avoid 
screening.52 Patients with medium or large varices 
require primary prevention with non-selective beta 
blockers or endoscopic band ligation. The role of 
carvedilol remains unclear.52 Furthermore, platelet 
levels <100,000 can increase risk for surgery. 
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In a study, it was demonstrated that in patients 
with ascitic fluid protein <15 g/L and without prior 
SBP, norfloxacin (400 mg/day) reduces the risk of 
SBP and improves survival. In these patients, long-
term primary prophylaxis should be considered.41 
Empirical antibiotics should be started immediately 
following the diagnosis of SBP. Furthermore, 
albumin (1.5 g/kg at diagnosis and 1 g/kg on Day 3) 
should be administered in order to decrease the 
risk of HRS.41 
The presence of hepatic encephalopathy can be 
extremely subtle. Precipitating factors including 
dehydration, infection, and variceal bleeding 
should be avoided or addressed as soon as 
possible. The ultimate treatment for cirrhosis is liver 
transplantation, and excellent long-term results 
have been demonstrated.53 It should be considered 
in patients with decompensated cirrhosis. The final 
decision depends upon the severity of the liver 
disease and the absence of contraindications.4
Patients who develop HCC should be managed 
according to the Barcelona Clinic Liver Cancer 
(BCLC) staging system.31 Single HCC lesions in 
Child–Pugh A patients are eligible for resection or 
ablation. Intermediate stage disease patients are 
offered locoregional therapy including transarterial 
chemoembolisation or radioembolisation. In 
advanced or metastatic disease, sorafenib is the 
only remaining option; it improves median overall 
survival from 6 to 9 months. In patients with lesions 
that meet the ‘Milan criteria’ liver transplantation 
should be considered.31 
PROGNOSIS 
The prognosis of patients with compensated 
cirrhosis is excellent. Transition from the 
compensated to the decompensated stage occurs 
at a rate of 5–7% per year.11 The median survival 
rate in compensated cirrhosis is >12 years.11 
Once patients develop complications of cirrhosis, 
such as ascites, variceal bleeding, or HRS, they are 
considered to have decompensated cirrhosis and 
their prognosis is worse. 
Two models are commonly used for prognosis 
evaluation: the Child–Pugh classification and 
the Model for End-Stage Liver Disease (MELD). 
The Child–Pugh classification includes the 
variables serum albumin and bilirubin, ascites, 
encephalopathy, and prothrombin time.54 The 
ranges from 5 to 15, and patients are divided into 
Child–Pugh A (score 5–6), B (score 7–9), or C 
(score 10–15). One-year survival rates for Child–
Pugh A, B, and C patients are 100%, 80%, and 
45%, respectively.55 MELD score is calculated 
using bilirubin levels, creatinine, and international 
normalised ratio.56 It is now used for prioritising 
patients on the liver transplant waiting list. Patients 
with a MELD score of >10 should be referred to a 
liver transplant centre for evaluation.  
There is a growing interest in the use of non- 
invasive tests for the prognosis of chronic liver 
disease, particularly for TE in patients with 
cirrhosis.34 The Baveno VI consensus paper52 
introduced the term ‘compensated advanced 
chronic liver disease’ (cACLD). This term applies 
to patients with chronic liver disease at increased 
risk of developing clinically significant portal 
hypertension, defined as a hepatovenous pressure 
gradient of ≥10 mmHg. TE values <10 kPa in the 
absence of other known clinical signs rule out 
cACLD. Values between 10–15 kPa are suggestive 
of cACLD but need confirmation. Values >15 kPa 
are highly suggestive of cACLD. Patients with 
cACLD are at an increased risk for complications 
and should be referred to a liver disease specialist.52 
CONCLUSION 
Cirrhosis is the final stage of chronic liver disease. 
The aim of a clinician dealing with cirrhosis should 
be to prevent the development of major 
complications. A new trend in this field is the 
adoption of non-invasive techniques, e.g. TE for 
diagnosis of cirrhosis and follow-up of cirrhotic 
patients, as they are an emerging tool for risk 
stratification. In cirrhotic patients the performance 
of an ultrasonograph every 6 months remains 
of utmost importance for early detection of 
HCC. Decompensated patients have a dismal 
prognosis and should be referred to a specialised 
hepatological centre, as liver transplantation should 
be considered in these patients. 
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